Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbrdn Regulatory News (ABDN)

Share Price Information for Abrdn (ABDN)

Share Price is delayed by 15 minutes
Get Live Data
238.60    -2.40 (-1.00%)
Bid:
237.20
Ask:
237.60
Spread: 0.40 (0.169%)
Market Cap: £4.27b
ABDN Live PriceLast checked at - London Stock Exchange

Intraday Abrdn Share Chart

Governance Changes

26 Mar 2026 08:00

RNS Number : 1614Y
Aberdeen Group PLC
26 March 2026
Β 

Aberdeen Group plc

Β 

Governance Changes

Β 

Aberdeen Group plc ("Aberdeen" or the "Company") today provides an update on its Chair succession process and consequential interim governance changes.

Β 

At the Company's 2025 AGM, Sir Douglas Flint announced that he would not stand for re-election at the following year's AGM. In January 2026, the Company confirmed that Sir Douglas would step down as Chair and as a Director of the Company with effect from the conclusion of the Company's Board meeting on 28 April 2026.Β 

Β 

The process to select a permanent successor to Sir Douglas as Chair of the Company remains ongoing and the Company will provide further updates on this in due course.

Β 

In the interim, and until a permanent Chair is appointed, the Company confirms that Jonathan Asquith, Senior Independent Director, will assume the role of Chair of the Company, subject to regulatory approval, and Chair of the Nomination and Governance Committee with effect from the conclusion of the Company's Board meeting on 28 April 2026.

Β 

During the interim period, Hannah Grove, Non-Executive Director, will assume the role of Chair of the Remuneration Committee. John Devine, Non-Executive Director, will assume the role of Senior Independent Director and rejoin the Nomination and Governance Committee. Jonathan will step down as a member of the Audit and Risk Committee.

Β 

While performing the role of Chair, Jonathan will receive a fee of Β£475,000 per annum on a prorated basis in line with the Directors' Remuneration Policy approved by shareholders at the 2023 AGM. Jonathan will receive no additional director fees in relation to his other roles in the Company during the period of his interim appointment.

Β 

Jonathan Asquith said:Β "On behalf of the Board, I would like to thank Sir Douglas for his exceptional contribution to the Company since joining the Board in 2018. His chairmanship has played a pivotal role in repositioning Aberdeen for success as a leading UK wealth and investments group. On behalf of my colleagues on the Board, I wish him all the very best for the future.

Β 

I look forward to continuing to work with Jason and his team to ensure the Company doesn't miss a beat in the execution of its growth strategy."

Β 

Sir Douglas Flint said:Β "It has been a huge privilege to serve as Chair of Aberdeen. In what has been quite a journey, I am really proud of what the Board and the executive team with the support of our colleagues have achieved together, including simplifying the Group and sharpening our strategic priorities. Jason is leading a first-rate executive team, with a clear strategy aimed at building the UK's leading wealth and investments group. I would like to thank my Aberdeen colleagues for their commitment and support, and I wish Jonathan, Jason and everyone at Aberdeen continued success."

Β 

The Financial Conduct Authority has been notified of the appointment of Jonathan Asquith as Chair of the Company and the appointment of Hannah Grove as Chair of the Remuneration Committee. Their respective appointments are subject to receipt of relevant regulatory approvals.

Β 

This announcement is made pursuant to UKLR 6.4.6R.

Β 

26 March 2026

Β 

Enquiries:

Β 

Media

Duncan Young

Β 

Β 

+44 (0) 7920 868 865

Β 

Group Secretariat

Iain Jones

Β 

Β 

+44 (0) 7464 917 797

Β 

* Calls may be monitored and/or recorded to protect both you and us and help with our training. Call charges will vary.

Β 

Β 

END

Β 

LEI number of Aberdeen Group plc: 0TMBS544NMO7GLCE7H90

Β 

Notes to Editors

Β 

For the purposes of section 430(2B) of the Companies Act 2006, Sir Douglas Flint will receive his Chair fee (Β£475,000 per annum) on a prorated basis until 28 April 2026. He is not entitled to any payments for loss of office.

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCBIGDXSUDDGLU
Date   Source Headline
18th Feb 202611:14 amRNSForm 8.3 - British Land Co PLC, The
17th Feb 202610:54 amRNSForm 8.3 - LondonMetric Property plc
16th Feb 20261:29 pmRNSForm 8.3 - LondonMetric Property plc
16th Feb 20261:23 pmRNSForm 8.3 - British Land Co PLC, The
12th Feb 20261:20 pmRNSForm 8.3 - Oxford Biomedica plc
12th Feb 20261:17 pmRNSForm 8.3 - LondonMetric Property PLC
12th Feb 202611:50 amRNSForm 8.3 - International Personal Finance PLC
12th Feb 202611:45 amRNSForm 8.3 - British Land Co PLC, The
11th Feb 20269:58 amRNSForm 8.3 - British Land Co PLC, The
10th Feb 202611:31 amRNSForm 8.3 - British Land Co PLC, The
5th Feb 20261:52 pmRNSForm 8.3 Oxford Biomedica plc
3rd Feb 20261:48 pmRNSHolding(s) in Company
3rd Feb 202612:23 pmRNSForm 8.3 - Bluefield Solar Income Fund Limited
3rd Feb 202612:19 pmRNSForm 8.3 - Oxford Biomedica PLC
3rd Feb 202612:14 pmRNSForm 8.3 - International Personal Finance PLC
3rd Feb 202612:10 pmRNSForm 8.3 - British Land Co PLC, The
3rd Feb 202612:06 pmRNSForm 8.3 - Picton Property Income Limited
2nd Feb 202610:10 amRNSTotal Voting Rights
29th Jan 20261:39 pmRNSHolding(s) in Company
29th Jan 202612:19 pmRNSForm 8.3 - British Land Co PLC, The
29th Jan 202612:13 pmRNSForm 8.3 - Life Science REIT PLC
29th Jan 202612:04 pmRNSForm 8.3 - Auction Technology Group plc
28th Jan 20263:49 pmRNSHolding(s) in Company
28th Jan 202612:11 pmRNSForm 8.3 - Unite Group plc/The
28th Jan 202612:08 pmRNSForm 8.3 - Oxford Biomedica PLC
26th Jan 20261:25 pmRNSForm 8.3 - Unite Group plc, The
26th Jan 202612:01 pmRNSForm 8.3 - Picton Property Income Limited
26th Jan 202611:58 amRNSForm 8.3 - JTC plc
26th Jan 202611:53 amRNSForm 8.3 - International Personal Finance plc
22nd Jan 202610:55 amRNSForm 8.3 - JTC plc
21st Jan 202612:12 pmRNSForm 8.3 - Unite Group plc, The
21st Jan 202612:05 pmRNSForm 8.3 - Oxford Biomedica plc
21st Jan 202612:01 pmRNSForm 8.3 - JTC plc
21st Jan 20267:00 amRNSQ4 2025 AUMA and Flows Trading Update
19th Jan 20261:04 pmRNSHolding(s) in Company
19th Jan 202611:59 amRNSForm 8.3 - UNITE Group PLC/The
19th Jan 202611:56 amRNSForm 8.3 - Picton Property Income Limited
19th Jan 202611:48 amRNSForm 8.3 - Oxford Biomedica plc
19th Jan 202611:41 amRNSForm 8.3 - JTC PLC
19th Jan 202611:37 amRNSForm 8.3 - International Personal Finance PLC
19th Jan 202611:34 amRNSForm 8.3 - Empiric Student Property PLC
19th Jan 202611:27 amRNSForm 8.3 - Bluefield Solar Income Fund Limited
16th Jan 20269:43 amRNSForm 8.3 - UNITE Group PLC/The
16th Jan 20269:32 amRNSForm 8.3 - Oxford Biomedica plc
16th Jan 20269:25 amRNSForm 8.3 - International Personal Finance PLC
15th Jan 20269:21 amRNSForm 8.3 - Oxford Biomedica plc
14th Jan 20261:33 pmRNSForm 8.3 - Unite Group plc, The
14th Jan 20261:29 pmRNSForm 8.3 - Picton Property Income Limited (OPD)
14th Jan 20261:26 pmRNSForm 8.3 - JTC plc
14th Jan 20267:00 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.